Israeli regenerative medicine firm矩阵已与Tel Aviv University(TAU) technology transfer firmRamotfor a patent-pending 3D bioprinting technology.
According to地球，该技术将患者的干细胞和细胞外基质（ECM）用于生物植入物，以再生体内受损的器官和组织的再生。该方法目前正在美国和欧洲予以批准的专利申请流程
The agreement will see Matricelf receive the global rights to develop and produce the technology and to commercialize it for third parties, subject to meeting certain scientific and business milestones.
Tau的再生医学
TAU has been pioneering the field of 3D bioprinting for several years, recently赢得本年度医疗保健申请的医学，牙科category at the2021 3D印刷行业奖. The award was collected by the Satchi-Fainaro Lab at TAU for its breakthrough3D bioprinted glioblastoma modelto improve the treatment of brain cancer.
现在由Matricelf许可的技术是由Tau生物技术系的Tal Dvir教授和大学纳米技术中心负责人开发的。DVIR还是矩阵的创始人之一，也是该公司的首席科学官。
生物打印技术通过同时衍生出的3D打印细胞和ECM来起作用，从而产生活着的人体组织和器官。打印过程基于液体纳米粒子，可稳定印刷结构以实现高分辨率和精度。然后在打印后从结构中提取分子。
早在2019年，该技术已用于创建“world’s first” 3D printed heartcomplete with cells, blood vessels, ventricles, and chambers.
商业化技术
自2019年成立以来，矩阵一直在为自体（骨髓）基质和细胞植入各种医疗状况（包括脊髓损伤治疗）开发个性化平台。该公司获得的专利技术是八年研究的高潮和1200万美元的赠款。
通过其与τ的Ramot最新协议,垫子上ricelf will receive the global rights and exclusivity to develop Dvir’s bioprinting technology and commercialize it for third parties. The firm will commit to signing at least one commercialization agreement with a third party, subject to approval from Ramot, within 36 months from the date of the agreement.
The technology is currently undergoing a patent application process in the US and Europe. Matricelf CEO Dr Asaf Toker told Globes:
“将技术应用于公司的发展，主要是通过治疗脊髓的伤害，以及向该行业的各个合作伙伴进行商业化，从而大大提高了在可预见的将来增强公司价值的潜力它是该领域领先的全球球员的地位。”
再生医学的进步
展望3D打印的未来, bioprinting has been predicted by numerous additive manufacturing leaders to play an important role in the next frontier of healthcare. In the last few months alone, researchers have developednew bioinks specifically for bioprinting blood vessels, and3D printed living brain cells在该技术的“有希望的发展”中。
Several 3D printing firms at the forefront of the regenerative medicine space have also made significant gains in recent months. In October, 3D bioprinting firm比科曾是granted two new patents用于使用对温度敏感的生物键的生物打印，而3D打印机制造商3D Systemsunveiled plans to扩展其生物打印程序在获取3D生物打印技术开发人员之后体积生物技术.
In November, meanwhile, 3D bioprinting start-upBrintersought toopen up the accessibility of bioprinting凭借其新的入门级3D打印机，Brinter核心和再生医学公司CTIBIOTECHannounced the development of anew 3D bioprinting platformto deliver personalized medicine for patients with colon cancer.
Regarding funding, Australian 3D bioprinting specialistInventia Life Sciencerecently raised $25 million to ramp up thelaunch of its RASTRUM bioprinterdesigned to address the US’ $40 billion biomedical R&D and drug discovery market, and earlier this month French regenerative medicine start-upHealshapeannouncedplans to raise $6.8 millionto develop its 3D bioprinted breast implants.
订阅3D打印行业newsletter有关增材制造中的最新消息。雷电竞充值您也可以通过关注我们来保持联系Twitterand liking us onFacebook.
寻找添加剂制造业的职业？雷电竞充值访问3D Printing Jobsfor a selection of roles in the industry.
Subscribe to ourYouTube频道for the latest 3D printing video shorts, reviews and webinar replays.
Featured image shows特拉维夫大学3D生物打印心脏。照片AFP/Jack Guez。
